Aspirin for the Control of Platelet Activation and Prevention of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Current Insights and Rationale for Future Studies

Raffaele Landolfi; Leonardo Di Gennaro; Linda Novarese; Carlo Patrono

doi:10.1055/s-2006-939436

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2006; 32(3): 251-259
DOI: 10.1055/s-2006-939436

Aspirin for the Control of Platelet Activation and Prevention of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Current Insights and Rationale for Future Studies

Raffaele Landolfi¹ ^, ² , Leonardo Di Gennaro² , Linda Novarese² , Carlo Patrono³

¹Professor
²Institute of Internal Medicine and Geriatrics, Catholic University School of Medicine, Rome, Italy
³Department of Pharmacology, University of Rome “La Sapienza,” Rome, Italy

Abstract

ABSTRACT

Polycythemia vera and essential thrombocythemia are chronic myeloproliferative disorders characterized by a relatively benign clinical course that may be complicated by arterial and venous thromboses. A thrombotic diathesis often manifests at diagnosis or in the preclinical phase of the myeloproliferative disease. Peculiar microcirculatory disturbances such as erythromelalgia and visual and hearing symptoms also commonly occur in these patients, and are highly responsive to aspirin. In a placebo-controlled trial in relatively low-risk polycythemic subjects, low-dose aspirin recently was shown to reduce the incidence of both arterial and venous thrombosis with a limited increase of the hemorrhagic risk. Due to its favorable benefit/risk profile, low-dose aspirin should be prescribed to all patients with polycythemia vera who have no contraindication to this treatment. Future studies should assess primarily the efficacy and safety of aspirin in essential thrombocythemia, and test the possible use of more aggressive antithrombotic strategies in high-risk polycythemic patients.

KEYWORDS

Polycythemia vera - essential thrombocythemia - aspirin - platelet activation - arterial thrombosis - venous thrombosis

Volltext

Referenzen

REFERENCES

1 Michiels J J, Barbui T, Finazzi G et al.. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leuk Lymphoma. 2000; 36 239-253
2 Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002; 100 2292-2302
3 Ania B J, Suman V J, Sobell J L et al.. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989. Am J Hematol. 1994; 47 89-93
4 Mesa R A, Silverstein M N, Jacobsen S J et al.. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol. 1999; 61 10-15
5 Harrison C N. Current trends in essential thrombocythaemia. Br J Haematol. 2002; 117 796-808
6 Spivak J L. Polycythemia vera: myths, mechanisms, and management. Blood. 2002; 100 4272-4290
7 Chievitz E, Thiede T. Complications and causes of death in polycythemia vera. Acta Med Scand. 1962; 172 513-523
8 Schafer A I. Bleeding and thrombosis in myeloproliferative disorders. Blood. 1984; 64 1-12
9 Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment. Crit Rev Oncol Hematol. 1995; 20 203-222
10 Pearson T C, Weiherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia vera. Lancet. 1978; 2 1219-1222
11 Elliott M A, Tefferi A. Thrombosis and haemorrage in polycythemia vera and essential thrombocythemia. Br J Haematol. 2005; 128 275-290
12 Michiels J J, Abels J, Steketee J et al.. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985; 102 466-471
13 Michiels J J, Koudstaal P J, Mulder A H, van Vliet H HDM. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology. 1993; 43 1107-1110
14 Michiels J J, van Genderen P JJ, Jansen P H, Koudstaal P J. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk Lymphoma. 1996; 22(suppl 1) 47-56
15 Koudstaal P J, Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Hemost. 1997; 23 365-370
16 Scheffer M G, Michiels J J, Simoons M L, Roelandt J RCT. Thrombocythemia and coronary artery disease. Am Heart J. 1991; 122 573-576
17 Van Genderen P J, Mulder P G, Waleboer M et al.. Prevention and treatment of thrombotic complications in essential thrombocythemia: efficacy and safety of aspirin. Br J Haematol. 1997; 97 179-184
18 Gruppo Italiano Studio Policitemia . Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995; 123 656-664
19 Patrono C, Ciabattoni G, Pugliese F et al.. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest. 1986; 77 590-594
20 Landolfi R, Ciabattoni G, Patrignani P et al.. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood. 1992; 80 1965-1971
21 Rocca B, Ciabattoni G, Tartaglione R et al.. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995; 74 1225-1230
22 Van Genderen P JJ, Prins F J, Mihiels J J, Schroer K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999; 104 438-441
23 Patrono C, Ciabattoni G, Patrignani P et al.. Eicosanoid biosynthesis and metabolism in myeloproliferative disorders. Ann NY Acad Sci. 1994; 744 229-236
24 Landolfi R, Marchioli R, Kutti J et al.. Efficacy and safety of low dose aspirin in polycythemia vera. N Engl J Med. 2004; 350 114-124
25 Vane J R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971; 231 232-235
26 Burch J W, Stanford N, Majerus P W. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978; 61 314-327
27 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982; 69 1366-1372
28 Smith W L. Prostanoid biosynthesis and mechanisms of action. Am J Physiol. 1992; 263 181-191
29 Patrono C, Ciabattoni G, Patrignani P et al.. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985; 72 1177-1184
30 FitzGerald G A, Oates J A, Hawiger J et al.. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983; 71 676-688
31 Pedersen A K, FitzGerald G A. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984; 311 1206-1211
32 Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994; 330 1287-1294
33 Patrono C, Coller B, FitzGerald G A et al.. Platelet-active drugs: the relationship among dose, effectiveness and side effects: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004; 126 234S-264S
34 Antithrombotic Trialist's Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324 71-86
35 Patrono C, Garcia Rodriguez L, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353 2373-2383
36 García Rodríguez L A, Hernández-Díaz S, de Abajo F J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52 563-571
37 Patrono C, Bachmann F, Baigent C et al.. Expert consensus document on the use of antiplatelet agents. Eur Heart J. 2004; 25 166-181
38 Peto R, Gray R, Collins R et al.. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ. 1988; 296 313-316
39 Steering Committee of the Physicians' Health Study Research Group . Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321 129-135
40 The Medical Research Councils' General Practice Framework . Thrombosis prevention trial: randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998; 351 233-241
41 Hansson L, Zanchetti A, Carruthers S G et al.. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351 1755-1762
42 Collaborative Group of the Primary Prevention Project . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001; 357 89-95
43 Sanmuganathan P S, Ghahramani P, Jackson P R et al.. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001; 85 265-271
44 Ridker P M, Cook N R, Lee I M et al.. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352 1293-1304
45 Van Genderen P JJ, Michiels J J, van Strik R, Lindemans J, van Vliet H HDM. Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemost. 1995; 73 210-214
46 Van Genderen P JJ, Lucas I S, van Strik R et al.. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation. Thromb Haemost. 1996; 76 333-338
47 Michiels J J. Erythromelalgia and thrombocythemia: a disease of platelet prostaglandin metabolism. Semin Thromb Hemost. 1997; 23 335-338
48 Tartaglia A, Goldberg J, Berk P, Wasserman L. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986; 23 172-176
49 Touraine F, Moldovan D, Touraine P, Chenot P, Bonnaud F. Aspirin and non steroidal anti-inflammatory drugs hypersensitivity review (2002-2004). Allergy Immunol. 2005; 37 279-282
50 Chan F K, Ching J Y, Hung L C et al.. Clopidogrel versus aspirin and omeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005; 352 238-244
51 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005; 23 2224-2232
52 Harrison C N, Campbell P J, Buck G et al.. A randomized comparison of hydroxyurea with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353 33-45
53 Michiels J J, Berneman Z, Schroyens W, van Vliet H HDM. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythemia and polycythemia vera. Platelets. 2004; 15 67-84
54 Michiels J J, Budde U, van der Planken M, Schroyens W, Bernaman Z. Acquired von Willebrand Syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol. 2001; 14 401-436
55 Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005; 353(1) 85-86
56 Cortelazzo S, Viero P, Finazzi G et al.. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990; 8 556-562
57 Bauer K A. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med. 2001; 135 367-373
58 Nicolaides A N. Thrombophilia and venous thromboembolism. International Consensus Statement. Intern Angiol. 2005; 24 1-26
59 Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol. 1991; 63 101-106
60 Van Genderen P JJ, Michiels J J. Erythromelalgic, thrombotic and hemorrhagic thrombocythemia. Presse Med. 1994; 23 73-77
61 Budde U, Schaefer G, Mueller N et al.. Acquired von Willebrand's disease in myeloproliferative syndrome. Blood. 1984; 64 981-985
62 Budde U, Dent J A, Berkovitz S D et al.. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986; 68 1213-1217
63 Fabris F, Casonato A, Del Ben M G et al.. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis. Br J Haematol. 1986; 63 75-83
64 Van Genderen P JJ, Michiels J J, van der Poel-van de Luitgaarde S CAMP, van Vliet H HDM. Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia. Ann Hematol. 1994; 69 81-84
65 Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355 1295-1302
66 Grady D, Wenger N K, Herrington D et al.. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000; 132 689-696
67 The ESPS . 2 Group. European Stroke Prevention Study 2. Efficacy and safety data. Secondary endpoints. J Neurol Sci. 1997; 151 S1-S7
68 Jacobson A K. Platelet ADP receptor antagonists: ticlopidine and clopidogrel. Best Pract Res Clin Haematol. 2004; 17 55-64
69 Kralovics R, Passamonti F, Buser A S et al.. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352 1779-1790
70 James C, Ugo V, Le Couedic J-P et al.. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature. 2005; 434 1144-1148
71 Levine R L, Wadleigh M, Cools J et al.. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005; 7 387-397
72 Baxter E J, Scott L M, Campbell P J et al.. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365 1054-1061
73 Campbell P J, Scott L M, Buck G et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005; 366 1945-1953
74 James C, Ugo V, Casadevall N, Constantinesco S N, Vainchenker W A. JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005; 11 546-554

Raffaele LandolfiM.D.

Institute of Internal Medicine, Haemostasis Research Center, Catholic University School of Medicine

Largo Agostino Gemelli 8, 00168 Rome, Italy

eMail: rlandolfi@rm.unicatt.it